Harm Reduction International and APDES will organise the 26th edition of the Harm Reduction International Conference (HR19); the event will take place in Porto, between April 28th and May 1st, 2019.

For international visitors, this conference will be a unique opportunity to learn about the benefits and lessons learned from Portugal’s progressive approach to drug policy and harm reduction, which included the decriminalisation of the possession and use of all drugs. Since 2001, the country has shown us that decriminalisation partnered with harm reduction can reduce HIV and overdose rates and increase access to vital health and social services. The approach has also highlighted the gaps in this policy-first approach and the need to include people who use drugs in policy making and other decisions about their health and rights. 

For locals, the conference will be an exceptional opportunity for community groups, networks of people who use drugs, healthcare and social services stakeholders, law enforcement officials, academics and the wider population to learn about other progress and innovation around the world and to share their own expertise and experience with a global audience. HR19 will also provide a rare opportunity for networking among harm reductionists from Lusophone countries.

Held once every two years in a different country around the world, the Harm Reduction International Conference is the only global meeting for knowledge-sharing, networking, and discussion of best practices in the field of harm reduction. The last conference in Montreal in 2017 was attended by more than 1000 delegates from over 70 countries, including medical and policy experts, harm reduction practitioners, campaigners, and people who use drugs.

HRI and APDES will publish further details about registration and abstract submission by the end of April 2018.

About Harm Reduction International

Harm Reduction International is a world-leading non-governmental organisation working to promote and expand support for harm reduction as well as reduce drug related harms by promoting evidence-based public health policies and practices, and human rights-based approaches to drug policy.